Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines

被引:0
|
作者
Solish, Nowell [1 ]
Kane, Michael A. C. [2 ]
Biesman, Brian S. [3 ]
Brown, Jessica [4 ]
Gallagher, Conor J. [4 ]
机构
[1] Univ Toronto, Div Dermatol, 66 Ave Rd, Toronto, ON M5R 3N8, Canada
[2] Manhattan Eye Ear & Throat Hosp, Dept Plast Surg, New York, NY USA
[3] Vanderbilt Univ, Dept Ophthalmol Dermatol & Otolaryngol, Sch Med, Nashville, TN USA
[4] Revance Therapeut Inc, Newark, CA USA
关键词
BOTULINUM-TOXIN; EYEBROW POSITION; FACIAL ANATOMY; OPEN-LABEL; PHASE-3; SHAPE; DURATION;
D O I
10.1093/asj/sjab362
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Botulinum toxin type A (BoNTA) injections for the treatment of facial lines may lead to pleasant or undesirable changes in eyebrow height and position. Objectives: The aim of this study was to evaluate the impact of glabellar injection of DaxibotulinumtoxinA for Injection (DAXI), a novel BoNTA formulation, on eyebrow position and frontalis activity. Methods: This study involved the post hoc analysis of adult patients from the Phase 2a forehead lines (FHL, N = 60) and open-label safety (OLS, N = 175) studies who received a single dose of DAXI 40 U to the glabella and for whom facial photographs were taken at rest and at maximum eyebrow elevation. Median vertical and horizontal displacement of the brows and median forehead strain (an objective quantitative assessment of frontalis activity) from baseline to 2 weeks after glabellar DAXI injection were measured. Results: Two weeks after glabellar DAXI injection, vertical eyebrow movement (at rest) of the lateral brow was observed. In both studies, vertical movement was greatest in the lateral (0.6-0.9 mm) and mid (0.5-0.7 mm) brow regions; movement in the medial brow was negligible (0-0.23 mm). In both studies, a graded reduction in forehead strain was observed 2 weeks post glabellar DAXI injection, with the greatest reduction being in the lower segment (FHL, -73%; OLS, -82%). Treatment with DAXI showed improvements in FHL wrinkle severity. Conclusions: Glabellar injection of DAXI showed a positive reduction in dynamic frontalis activity that maintained or had a positive effect on eyebrow position. Vertical movement of the brow was suggestive of an improved eyebrow shape with a mild lateral arch.
引用
收藏
页码:S1 / S9
页数:9
相关论文
共 50 条
  • [41] DOSING OF ABOBOTULINUMTOXINA FOR LONG-TERM TREATMENT OF GLABELLAR LINES: INJECTION PRACTICES FROM THE APPEAL NONINTERVENTIONAL STUDY
    Gubanova, Elena
    Tabet, May Haddad
    Bergerova, Yvonne
    Moiseieva, Olena
    Chemeris, Andrey
    Sanches, Elena
    Sharova, Alisa
    Raymond, Romain
    Prygova, Inna
    Carlisle, Ian
    TOXICON, 2018, 156 : S41 - S41
  • [42] Simultaneous treatment of moderate-to-severe horizontal frontalis lines, glabellar lines, and lateral canthal lines with onabotulinumtoxinA, from the subject's perspective: Patient-reported satisfaction and impact outcomes from a phase 3 double-blind study
    Dayan, Steven
    Ogilvie, Patricia
    Rivkin, Alexander Z.
    Yoelin, Steven G.
    Ferrusi, Ilia L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB262 - AB262
  • [43] Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines
    Dayan, Steven
    Joseph, John
    Moradi, Amir
    Lorenc, Z. Paul
    Coleman, Kyle
    Ablon, Glynis
    Kaufman-Janette, Joely
    Cox, Sue Ellen
    Campbell, Andrew
    Munavalli, Girish
    Prygova, Inna
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (06) : 2407 - 2416
  • [44] Two phase 3, randomized, double-blind, placebo-controlled, multicenter trials to evaluate the efficacy and safety of daxibotulinumtoxinA for injection to treat moderate to severe glabellar lines (SAKURA 1 and 2)
    Solish, Nowell
    Bertucci, Vince
    Humphrey, Shannon
    Bhatia, Ashish
    Biesman, Brian
    Joseph, John
    Kaufman-Janette, Joely
    Glogau, Richard
    Park, Eric
    Rubio, Roman
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB306 - AB306
  • [45] Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program
    Cohen, Joel L.
    Green, Lawrence J.
    Beer, Kenneth R.
    Liu, Yan
    Gallagher, Conor J.
    DERMATOLOGIC SURGERY, 2021, 47 (04) : 511 - 515
  • [46] Assessment of the onset, spread, efficacy, and pain upon injection of abobotulinumtoxina and onabotulinumtoxina for the treatment of dynamic frontalis rhytids using a novel frontalis activity measure
    Nestor, Mark
    Ablon, Glynis
    Collins, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB21 - AB21
  • [47] The Efficacy and Safety of a New US Botulinum Toxin Type A in the Retreatment of Glabellar Lines Following Open-Label Treatment
    Rubin, Mark G.
    Dover, Jeffrey S.
    Glogau, Richard G.
    Goldberg, David J.
    Goldman, Mitchel P.
    Schlessinger, Joel
    JOURNAL OF DRUGS IN DERMATOLOGY, 2009, 8 (05) : 439 - 444
  • [48] Local anaesthetics use does not suppress muscle activity following an ankle injection
    Stone, David A.
    Abt, John P.
    House, Anthony J.
    Akins, Jonathan S.
    Pederson, Jonathan J.
    Keenan, Karen A.
    Lephart, Scott M.
    KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY, 2013, 21 (06) : 1269 - 1278
  • [49] Local anaesthetics use does not suppress muscle activity following an ankle injection
    David A. Stone
    John P. Abt
    Anthony J. House
    Jonathan S. Akins
    Jonathan J. Pederson
    Karen A. Keenan
    Scott M. Lephart
    Knee Surgery, Sports Traumatology, Arthroscopy, 2013, 21 : 1269 - 1278
  • [50] OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study
    Ogilvie, Patricia
    Rivkin, Alexander Z.
    Dayan, Steven
    Yoelin, Steven G.
    Weichman, Barry M.
    Garcia, Julie K.
    DERMATOLOGIC SURGERY, 2019, 45 (05) : 689 - 699